Edgewise Therapeutics (EWTX) Operating Expenses (2020 - 2026)

Edgewise Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $54.1 million in Q1 2026.

• Quarterly Operating Expenses rose 17.75% year-over-year to $54.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $199.6 million (up 17.36% YoY) and the FY2025 annual result came in at $191.4 million, up 20.51% from the prior year.
• Operating Expenses slipped to $54.1 million in Q1 2026 per EWTX's latest filing, from $56.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $56.0 million in Q4 2025 and troughed at $14.8 million in Q1 2022.
• A 5-year average of $34.7 million and a median of $34.8 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses jumped 116.22% in 2022, then advanced 11.82% in 2025.
• Over 5 years, Operating Expenses stood at $22.1 million in 2022, then surged by 53.37% to $33.9 million in 2023, then surged by 34.49% to $45.5 million in 2024, then gained by 22.92% to $56.0 million in 2025, then declined by 3.33% to $54.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $54.1 million, $56.0 million, and $46.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.